SCHEMBL3225838

SCHEMBL3225838

N#Cc1cccc2c1C(C(N)=O)=C[N]2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
RECQL P46063 1/20 0.35
NOTUM Q6P988 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CDC7 O00311 1/20 0.33
SLC9A1 P19634 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PARP1 P09874 1/20 0.33
ALDH1A1 P00352 1/20 0.32
GRIA1 P42261 1/20 0.31
CACNG8 Q8WXS5 1/20 0.31
TRPA1 O75762 2/20 0.31
PDK2 Q15119 1/20 0.31
MAP2K1 Q02750 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CHUK O15111 1/20 0.31
CYP11B2 P19099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14313208 0.77 PIM1 (0.38) PARP1CA1CA2
SCHEMBL3222329 0.72 BCAT2 (0.38) KDM4ERECQLMEN1KMT2AGAA
SCHEMBL3227204 0.70 PARP2 (0.37) PARP1CA1CA2
SCHEMBL3218786 0.67 CSNK1A1 (0.31)
SCHEMBL3225835 0.67 CDC7 (0.33) KDM4ERECQLNOTUMCDC7SLC9A1
SCHEMBL31287988 0.66 PARP1 (0.43) KDM4EMEN1KMT2ACDC7PARP1
SCHEMBL27710598 0.65 KAT6A (0.41) CDC7SMN1; SMN2PARP1ALDH1A1PDK2
SCHEMBL30962768 0.64 XDH (0.40) KDM4ERECQLMEN1KMT2AGAA
SCHEMBL262368 0.64 NPC1 (0.58) KDM4ECDC7GAASMN1; SMN2ALDH1A1
SCHEMBL12503763 0.63 NPC1 (0.44) KDM4ECDC7SLC9A1GAAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 KDM4E 2494/4885RECQL 219/4885NOTUM 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.